[Neurotropic properties of fluphenazine].
D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001158:Arteries; D001794:Blood Pressure / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced; D002415:Cats; D002746:Chlorpromazine / Q000008:administration & dosage*; D003214:Conditioning, Classical / Q000187:drug effects; D003864:Depression, Chemical; D004285:Dogs; D004357:Drug Synergism; D004558:Electric Stimulation; D004569:Electroencephalography; D004837:Epinephrine / Q000037:antagonists & inhibitors; D004924:Escape Reaction / Q000187:drug effects; D005476:Fluphenazine / Q000008:administration & dosage* / Q000633:toxicity*; D006591:Hexobarbital / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010276:Parasympatholytics / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012964:Sodium / Q000494:pharmacology*; D013564:Sympathetic Nervous System / Q000187:drug effects; D013874:Thiopental / Q000494:pharmacology*; D013997:Time Factors; D014149:Tranquilizing Agents / Q000494:pharmacology*; D014268:Trifluoperazine / Q000494:pharmacology / Q000633:toxicity*; D014839:Vomiting / Q000517:prevention & control
D010276:Parasympatholytics; D014149:Tranquilizing Agents; D014268:Trifluoperazine; D012964:Sodium; D006591:Hexobarbital; D000661:Amphetamine; D013874:Thiopental; D001058:Apomorphine; D005476:Fluphenazine; D002746:Chlorpromazine; D009638:Norepinephrine; D004837:Epinephrine
O neĭrotropnykh svoistvak ftorfenazina.